Nurkka A, Ahman H, Korkeila M, Jäntti V, Käyhty H, Eskola J
National Public Health Institute, Helsinki, Finland.
Pediatr Infect Dis J. 2001 Jan;20(1):25-33. doi: 10.1097/00006454-200101000-00006.
To study the ability of seven-valent experimental pneumococcal polysaccharide CRM197 protein conjugate vaccine (PncCRM) to induce antibodies in serum and saliva of infants.
Sixty Finnish infants received Pnc-CRM vaccine at 2, 4 and 6 months of age and were boosted with PncCRM (n = 30) or pneumococcal polysaccharide (PncPS) (n = 29) vaccine at the age of 15 months. Serum IgG antibody concentrations to vaccine serotypes 4, 6B, 9V, 14, 18C, 19F and 23F were measured by enzyme immunoassay at 2, 4, 6, 7, 15, 16 and 24 months of age. Salivary IgA, IgG and secretory Ig antibody titers at 7 and 16 months of ages were analyzed by enzyme immunoassay against the same serotypes, except 23F.
PncCRM induced systemic immune responses and immunologic memory. At 7 months of age 69 to 100% of children, depending on the serotype, had serum IgG antibody concentrations exceeding the value of 1.0 microg/ml. At 15 months the titers were still higher than before the vaccinations. Booster doses of either PncPS or PncCRM induced an increase in antibody concentrations. The titers were still elevated at 24 months of age. Salivary IgA and IgG antibodies were found rarely at 7 months of age, but in up to 80% of samples taken at 16 months of age, depending on the serotype and nature of the booster vaccine. Salivary IgG correlated with IgG in serum, supporting the theory that salivary IgG is derived from serum. Salivary IgA and secretory Ig correlated positively, which indicates that IgA was locally produced.
PncCRM induces both systemic and mucosal immune responses in infants.
研究七价实验性肺炎球菌多糖CRM197蛋白结合疫苗（PncCRM）诱导婴儿血清和唾液中抗体的能力。
60名芬兰婴儿在2、4和6月龄时接种Pnc-CRM疫苗，并在15月龄时分别用PncCRM（n = 30）或肺炎球菌多糖（PncPS）（n = 29）疫苗进行加强免疫。在2、4、6、7、15、16和24月龄时，采用酶免疫测定法检测血清中针对疫苗血清型4、6B、9V、14、18C、19F和23F的IgG抗体浓度。在7和16月龄时，采用酶免疫测定法分析唾液中针对相同血清型（23F除外）的IgA、IgG和分泌型Ig抗体滴度。
PncCRM诱导了全身免疫反应和免疫记忆。在7月龄时，69%至100%的儿童（取决于血清型）血清IgG抗体浓度超过1.0μg/ml。在15月龄时，抗体滴度仍高于接种疫苗前。PncPS或PncCRM加强剂量均诱导抗体浓度增加。在24月龄时，抗体滴度仍升高。7月龄时很少发现唾液IgA和IgG抗体，但在16月龄时采集的样本中，高达80%的样本（取决于血清型和加强疫苗的性质）可检测到。唾液IgG与血清IgG相关，支持唾液IgG来源于血清的理论。唾液IgA和分泌型Ig呈正相关，表明IgA是局部产生的。
PncCRM可诱导婴儿产生全身和黏膜免疫反应。
